|View printer-friendly version|
|June 05, 2005 11:28 a.m.|
|Teva Comments On Clarithromycin Er Preliminary Injunction|
Jerusalem, Israel, June 5, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Northern Illinois has granted Abbott's motion for a preliminary injunction related to Teva's generic Clarithromycin Extended Release Tablets pending a trial on the merits or further court order. The injunction is based on Abbott's enforcement of one extended release formulation patent that Teva has asserted are invalid.